Matthew Porteus (Credit: Timothy Archibald for Stanford Children's)
Versant teams up with Stanford gene editing experts on a $45M next-gen play — marrying CRISPR and AAV to fix sickle cell
When a researchers talk about gene editing, they’re usually thinking about several steps. First you need to zero in on the defective gene; then, depending …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
